INSIGHTS ON DRUG DEVELOPMENT
-
![GettyImages-1690936576-inspection-in-factory]( "Why Audit Success No Longer Predicts Clinical-Stage Performance")
Why Audit Success No Longer Predicts Clinical-Stage PerformancePassing inspections no longer signals that a growth-stage biotech can sustain clinical-stage complexity. The gap between audit readiness and operational readiness opens quietly.
-
![peptides-preclinical-develop-GettyImages-2264393871]( "Screening For Amorphous Drug Substance")
Screening For Amorphous Drug SubstanceIncorporate amorphous form screening early in development to unlock solubility advantages, improve bioavailability, and accelerate your path to market.
-
![Getty Images-1053434168_neurons]( "Nose To Brain (N2B) Drug Delivery – Benefits And Challenges")
Nose To Brain (N2B) Drug Delivery – Benefits And ChallengesDelve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).
-
![icellis family]( "Streamline Your Workflow With An Innovative Fixed-Bed System")
Streamline Your Workflow With An Innovative Fixed-Bed SystemDiscover how an innovative fixed-bed system streamlines workflows and supports consistent, high-yield manufacturing across a range of applications.
-
AI Based Screening And Selection Of Co-Formers For Co-Crystallization11/4/2025
Explore how AI and quantum chemistry are accelerating co-crystal screening and solving solubility challenges in drug development, as well as key technical considerations for identifying optimal co-formers.
-
Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD)5/6/2026
Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.
-
Automated Testing For Compound Toxicity Effects3/17/2025
Explore how anti-cancer drugs' toxic effects on intestinal cells limit dosages as well as how 3D organoids and assay automation can enhance drug development by improving testing processes.
-
Lipid Nanoparticles For Pulmonary Delivery Of mRNA7/1/2026
Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.
-
Optimize Process Performance And Maximize HCP Removal8/27/2026
Compare filtration strategies and explore how filter selection affects host cell protein removal, processing efficiency, and the balance between impurity clearance and filtration performance.
DRUG DEVELOPMENT SOLUTIONS
-
![GettyImages-1602744313 assay]( "Cell-Based Assay Development And Testing")
Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.
-
![Nasal Dosage Form Development]( "Nasal Dosage Form Development")
Upperton have developed UpperNose™, a nasal product development approach designed to streamline the development process for nasal dosage forms.
-
![cdo key visual image_]( "CDO Services: Agile. Flexible. Focused On You.")
Successful development relies on a deep understanding of a molecule’s unique characteristics. We have the knowledge and expertise to realize the true potential of your molecule, regardless of its complexity.
-
![LSC-Cell-Line-Portfolio]( "Optimize Your Cell Line Strategy For Better Viral Vector Production")
Optimize your cell line strategy for better viral vector production.
-
MaxPeak™ Premier Columns utilize MaxPeak High Performance Surfaces that are designed to increase analyte recovery, sensitivity, and reproducibility by minimizing analyte/surface interactions that can lead to sample losses.
